What We Know About Tuberculosis Transmission: An Overview

Gavin Churchyard, *Aurum Institute*
Peter Kim, *National Institutes of Health*
Nippie Shah, *Emory University*
Roxana Rustomjee, *National Institutes of Health*
Neel R. Gandhi, *Emory University*
Barun Mathema, *Columbia University*
David Dowdy, *Johns Hopkins University*
Anne Kasmar, *Bill and Melinda Gates Foundation*
Vicky Cardenas, *Aurum Institute*

**Journal Title:** Journal of Infectious Diseases  
**Volume:** Volume 216, Number suppl_6  
**Publisher:** Oxford University Press (OUP): Policy B - Oxford Open Option C | 2017-10-01, Pages S629-S635  
**Type of Work:** Article | Final Publisher PDF  
**Publisher DOI:** 10.1093/infdis/jix362  
**Permanent URL:** https://pid.emory.edu/ark:/25593/tk31f

Final published version: http://dx.doi.org/10.1093/infdis/jix362

**Copyright information:**

© 2017 The Author.  
This is an Open Access work distributed under the terms of the Creative Commons Attribution 3.0 IGO License License  
(https://creativecommons.org/licenses/by/3.0/igo/).

Accessed April 14, 2019 7:12 AM EDT
What We Know About Tuberculosis Transmission: An Overview

Gavin Churchyard,1,2,4 Peter Kim,9 N. Sarita Shah,7 Roxana Rustomjee,7 Neel Gandhi,9 Barun Mathema,10 David Dowdy,9 Anne Kasmar,11 and Vicky Cardenas1

1Aurum Institute, Johannesburg, South Africa, 2School of Public Health, University of the Witwatersrand, Johannesburg, South Africa, 3Advancing Care & Treatment for TB/HIV, Johannesburg, South Africa, and 4South African Medical Research Council, Johannesburg, South Africa; 5Division of AIDS, National Institutes of Health, Bethesda, Maryland, and 6Johns Hopkins University, Baltimore, Maryland; 7Division of Global HIV and Tuberculosis, Centers for Disease Control and Prevention, Atlanta, Georgia, and 8Rollins School of Public Health, Emory University, Atlanta, Georgia, and 9Emory School of Medicine, Emory University, Atlanta, Georgia; 10Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, New York; and 11Bill and Melinda Gates Foundation, Seattle, Washington

Tuberculosis remains a global health problem with an enormous burden of disease, estimated at 10.4 million new cases in 2015. To stop the tuberculosis epidemic, it is critical that we interrupt tuberculosis transmission. Further, the interventions required to interrupt tuberculosis transmission must be targeted to high-risk groups and settings. A simple cascade for tuberculosis transmission has been proposed in which (1) a source case of tuberculosis (2) generates infectious particles (3) that survive in the air and (4) are inhaled by a susceptible individual (5) who may become infected and (6) then has the potential to develop tuberculosis. Interventions that target these events will interrupt tuberculosis transmission and accelerate the decline in tuberculosis incidence and mortality. The purpose of this article is to provide a high-level overview of what is known about tuberculosis transmission, using the tuberculosis transmission cascade as a framework, and to set the scene for the articles in this series, which address specific aspects of tuberculosis transmission.

Keywords. Tuberculosis; transmission.
addition, we should continue to conduct research to optimize delivery of effective interventions, as well as develop new tools that can maximize interrupting tuberculosis transmission.

In March 2016, the National Institutes of Health convened a workshop aimed at identifying the research needs for halting tuberculosis transmission, with the eventual aim of reducing new *M. tuberculosis* infections to zero. The purpose of this article is to give a high-level overview of the discussion at the workshop regarding what is known about tuberculosis transmission and to set the scene for the articles that address specific aspects of tuberculosis transmission. The lessons learned from studying tuberculosis transmission are also relevant to reducing transmission of other airborne pathogens.

**EPIDEMIOLOGY OF TUBERCULOSIS TRANSMISSION: A BRIEF HISTORY**

Robert Koch discovered *M. tuberculosis* in 1882. William Osler, in 1909, wrote that “all who mix with tuberculosis patients got infected, but remained well so long as they took care of themselves and kept the soil in a condition unfavorable for the growth of the seed” [8]. Over the intervening century of tuberculosis research, our understanding of tuberculosis transmission and disease progression has improved: in 1920, Devoto recognized that healthcare workers were at risk of developing tuberculosis; in 1934, Wells described the falling and evaporation times for droplet nuclei [9]; and Riley, in 1961, described the deposition of airborne bacteria in the lung [10] and, in 1960–1962, described aerial dissemination of *M. tuberculosis* in a tuberculosis ward [11, 12]. Chapman, in 1964, described the social and other factors associated with tuberculosis transmission in tuberculosis-affected households [13].

More recent achievements (circa mid-2000s) in this area include the phylogeographical classification of global *M. tuberculosis* strains and the advent of whole-genome sequencing for molecular tracking of tuberculosis outbreaks.

**TUBERCULOSIS TRANSMISSION CASCADE**

In this series, a simple cascade for tuberculosis transmission is proposed in which (1) a source case of tuberculosis (2) generates infectious particles (3) that survive in the air and (4) are inhaled by a susceptible individual (5) who may become infected and (6) who then has the potential to develop tuberculosis. Interventions that target bacterial, host, or behavioral catalysts of transmission will interrupt tuberculosis transmission and accelerate the decline in tuberculosis incidence and mortality [14]. In this article, this cascade of tuberculosis transmission will be used to describe who is transmitting, where transmission is occurring, and who is susceptible to infection and to disease progression. In answering these questions, we can understand what it will take to stop tuberculosis transmission (Figure 2).

**WHO IS TRANSMITTING?**

The infectiousness and duration thereof for a person with tuberculosis depend on host and bacterial factors. Persons with smear-positive pulmonary tuberculosis are highly infectious, and the degree of infectiousness is thought to increase with the degree of smear positivity. In a large study of household contacts in Peru, smear-positive index cases were associated with a higher risk of infection among household contacts, compared with smear-negative index cases, regardless of the age of the household contacts [15]. Persons with smear-negative tuberculosis cases may, however, also transmit tuberculosis [16]. Nevertheless, scale-up of sputum smear microscopy has not succeeded in achieving dramatic declines in tuberculosis incidence. Possible reasons for the lack of impact include the poor sensitivity of smear microscopy, particularly among HIV-infected persons and children, and the occurrence of many cases of transmission before people receive a tuberculosis diagnosis and treatment.

Persons with active pulmonary or laryngeal tuberculosis generate droplet nuclei that contain *M. tuberculosis* through...
coughing, singing, shouting, sneezing, or any other forceful expiratory maneuver that shears respiratory secretions from the airways, with coughing being the most efficient at generating infectious aerosols [16]. Appropriate treatment of individuals with infectious tuberculosis results in a rapid reduction in infectiousness [17]. Individuals with index tuberculosis cases who are HIV infected, particularly those with advanced immunosuppression, were hypothesized to be less likely than HIV-uninfected individuals with tuberculosis to transmit to household contacts, possibly because of a greater likelihood of having smear-negative tuberculosis and a shorter duration of infectiousness due to more rapid progression to death [18, 19].

Antiretroviral therapy reduces the risk of tuberculosis among people with HIV infection (PLHIV) by 67% and, if scaled up, may contribute to a reduction in tuberculosis case rates at a population level [20, 21]. Although there is preferential mixing of close contacts within age groups and sexes, in Southern Africa most M. tuberculosis infections appear to be associated with contact with adult men [22].

**WHERE IS TRANSMISSION OCCURRING?**

Robert Koch, in his Nobel Lecture, delivered in 1905, said that “tuberculosis has been called plainly, and quite justly, a disease of accommodation” [23], highlighting transmission of tuberculosis within tuberculosis-affected households. Today there is a wealth of evidence to support transmission of drug-susceptible and drug-resistant tuberculosis in households [15, 24, 25]. Transmission of tuberculosis to household contacts is most likely to occur when the index case is smear positive and the household contacts are <15 years of age [15, 26]. Despite a historical focus on household transmission, the overall proportion of tuberculosis transmissions that occur in households is estimated to be between 8% and 19% in countries with a high HIV prevalence, such as South Africa and Malawi [27]. In settings with a high tuberculosis burden, tuberculosis transmission is therefore more likely to occur outside the household, in schools, public transportation settings, workplaces, healthcare facilities, mines, and prisons [19, 26–33]. Nevertheless, targeting tuberculosis-affected households for tuberculosis screening, HIV testing, and referral for treatment of tuberculosis or M. tuberculosis infection remains a priority because of the high prevalence of tuberculosis and M. tuberculosis infection among household contacts. Transmission within hospitals and clinics can be reduced by using the FAST approach: Finding undiagnosed tuberculosis cases actively through cough surveillance and use of rapid molecular diagnostics, Separating safely, and providing appropriate Treatment [34]. Geographic areas with increased tuberculosis transmission (so-called hot spots) may be identified using...
WHO IS SUSCEPTIBLE?

Close contacts of infectious tuberculosis cases are susceptible to becoming infected and, if infected, to progressing to tuberculosis, particularly within the first year after exposure [36]. Among 95 contact investigation studies from countries of low and middle incomes, the prevalence of M. tuberculosis infection among contacts was 51.5%. Contacts who are <5 years of age or HIV infected have the greatest risk of developing tuberculosis [36]. Among countries with high burdens of tuberculosis and HIV infection, such as South Africa and Zambia, HIV-infected household contacts have a risk of progressing to tuberculosis that is almost 5-fold greater than that for HIV-uninfected household contacts [37]. In settings with a high tuberculosis burden, silica-exposed miners, particularly those with silicosis, have a high prevalence of M. tuberculosis infection [38, 39]. Many persons who are at high risk of developing tuberculosis can be identified on the basis of their medical history or with simple tests [14]. Currently, it is not possible to identify persons who have an increased risk of infection if exposed.

HALTING TRANSMISSION

Halting tuberculosis transmission is central to stopping the tuberculosis epidemic. As shown in Figure 2, it may be possible to target interventions to reduce the infectiousness or duration of infectiousness of tuberculosis cases, contact rates, and susceptibility of contacts. Contact between an infectious tuberculosis case and a susceptible person may occur because of clustering in space (such as in households, workplaces, and urban slums) or over time (such as in public transportation settings, among migrant workers, and during urbanization or displacement) [14]. Contact rates can be reduced through socioeconomic development leading to reduced crowding. Socioeconomic development also improves nutrition, reducing progression to tuberculosis. Improved infection control also accompanies socioeconomic development, particularly improved ventilation in areas where contact is likely to occur, such as healthcare facilities, public transportation settings, workplaces, and schools [5, 14]. Infectiousness and the duration of infectiousness can be reduced through early case detection and treatment by improving access to quality tuberculosis diagnostic and treatment services, use of quicker and more-sensitive diagnostic assays such as Xpert MTB/Rif, active case finding and linkage to care for appropriate treatment, and interventions to reduce attrition before starting treatment [6]. Susceptibility to tuberculosis can be reduced by addressing host factors such as HIV infection, diabetes, anti–tumor necrosis factor treatment, organ transplantation, renal dialysis, silicosis, illicit drug use, malnutrition, harmful alcohol use, and smoking. Susceptibility to tuberculosis can also be reduced by treating the underlying condition (eg, HIV infection and diabetes), by reducing key exposures (eg, silica dust, tobacco smoke, and indoor pollutants), and by providing preventive therapy for latent M. tuberculosis infection.

A number of intervention studies have attempted to reduce tuberculosis transmission at a population level by using combinations of case finding and preventive therapy interventions targeting at-risk groups or communities, with success ranging from no or minimal impact to large and sustained impact (Table 1) [40–51]. The variable success of the interventions in achieving a population-level impact may be due to poor targeting of risk groups, inadequate coverage, implementation of interventions that are not implemented or evaluated long enough to capture mass effect, and use of old tools, such as sputum microscopy.

NEW TOOLS

Advances in technology may allow more-effective targeting of the sources of tuberculosis transmission. The Xpert MTB/RIF test was initially heralded as a “game changer” in the diagnosis of tuberculosis, owing to its greater sensitivity than sputum smear microscopy [52, 53]. The roll out of Xpert MTB/RIF, however, has had limited impact on tuberculosis mortality and incidence to date, largely because of health system weaknesses, particularly those due to poor uptake of HIV testing and linkage to care for antiretroviral therapy. This highlights the need to strengthen health systems and develop new tools [54, 55]. The next-generation Xpert MTB/Rif (Ultra) cartridge is expected to be even more sensitive and could be a valuable tool to identify active and infectious cases, thereby allowing the prevention of transmission. Modeling suggests that new tuberculosis drugs and regimens for drug-susceptible and drug-resistant tuberculosis that are shorter and more efficacious may have a modest population-level impact [7, 56]. New tests for individuals with M. tuberculosis infection that predict who will progress to tuberculosis will allow treatment of infection to be targeted to those at greatest risk of developing tuberculosis [57]. Implementation of new, short-course regimens for treating latent M. tuberculosis infection, such as weekly high-dose isoniazid and rifapentine for 3 months or daily isoniazid and rifampicin for 3 months, potentially could have a profound effect on the tuberculosis epidemic, particularly if implemented at scale and coupled with active case finding and treatment of all forms of tuberculosis. Barriers to scaling up treatment of M. tuberculosis infection should be addressed, and innovative, affordable models of delivery that support scale up of treatment of M. tuberculosis infection should be evaluated [58]. New research tools, such as whole-genome sequencing, could help us understand global and local tuberculosis epidemiology better and thereby target...
interventions to reduce transmission more effectively [59]. Similarly, tuberculosis vaccines that prevent *M. tuberculosis* infection or disease among adolescents and adults may have a profound impact on the tuberculosis epidemic [60].

**CONCLUSION**

Robert Koch, in his Nobel Lecture, said that “amidst the persistently great variety in the ways and means of combating tuberculosis, it is yet necessary to ask what measures do indeed best satisfy the scientific requirements” [23]. More than 100 years later, we are still asking the same question. Although our understanding of tuberculosis transmission has improved substantially, many gaps remain. Subsequent articles in this series aim to identify these gaps and to describe the benefits (and obstacles) to filling them. One thing is certain: if we wish to end tuberculosis by 2035, a massive concerted effort is required today.

**Notes**

**Disclaimer.** The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the Department of Health and Human Services.

**Financial support.** This publication and workshop have been funded in whole or in part with Federal Funds from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH), Department of Health and Human Services under contract number HHSN272201100001G – Research Support Services for the Division of AIDS. Funding support was also provided in part by NIH grants: NIAID R01AI089349 (PI Gandhi), NIAID R01AI087465 (PI Gandhi), NIAIDK24AI114444 (PI Gandhi), Emory CFR P30Al050409 (PI JW Curran), and NHLBI T32 HL116271 (PI DM Guidot). The Bill & Melinda Gates Foundation provided funding for participant travel to the workshop.

---

**Table 1. Studies Evaluating Tuberculosis Interventions Intended to Achieve a Population-Level Impact**

<table>
<thead>
<tr>
<th>Country(ies), Year, Reference(s)</th>
<th>Setting</th>
<th>Design(s)</th>
<th>Intervention(s)</th>
<th>Outcome Measure(s)</th>
<th>Finding(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tunisia, 1963 [41, 42]</td>
<td>Urban slums (n = 153)</td>
<td>CRT (housing blocks)</td>
<td>IPT for 12 mo</td>
<td>Tuberculosis case rates (cases/1000)</td>
<td>2.3 cases/1000 in IPT arm vs 3.1 in placebo arm (25.8% reduction)</td>
</tr>
<tr>
<td>Greenland, 1966 [42–44]</td>
<td>Villages (n = 76)</td>
<td>CRT (villages)</td>
<td>2 courses of INH 400 mg twice weekly for 3 mo</td>
<td>Cumulative case rates</td>
<td>5.7% in IPT arm vs 8.3% in placebo arm (31.3% reduction)</td>
</tr>
<tr>
<td>US, 1967 [40, 41, 44]</td>
<td>Alaska, Bethel communities (n = 30)</td>
<td>CRT (households)</td>
<td>Household-wide IPT for 12 mo</td>
<td>Cumulative case rate</td>
<td>1.9% in IPT arm vs 4.67% in placebo arm (59.3% reduction)</td>
</tr>
<tr>
<td>US, 1986 [46]</td>
<td>Oregon, Burnside area</td>
<td>Before/after intervention (homeless shelters)</td>
<td>Mandatory tuberculosis screening and treatment of tuberculosis or <em>M. tuberculosis</em> infection among persons using homeless shelter</td>
<td>Case notification rate</td>
<td>29 cases/100 000 in 1995 vs 227 in 1985 (decline greater than that observed in other districts)</td>
</tr>
<tr>
<td>Zambia, 2005 [47]</td>
<td>Harare, high-density suburbs (n = 46)</td>
<td>CRT (suburbs)</td>
<td>Tuberculosis screening via mobile van or door to door</td>
<td>Tuberculosis prevalence, before vs after intervention for both arms combined</td>
<td>6.5 cases/1000 at baseline vs 3.7 after intervention (aRR, 0.59 [95% CI, 0.40–0.89])</td>
</tr>
<tr>
<td>Zambia and South Africa, 2006 [48]</td>
<td>Communities in South Africa and Zambia (n = 24)</td>
<td>CRT (communities), factorial design</td>
<td>(1) ECF vs non-ECF; (2) household care vs non-household care</td>
<td>(1) Tuberculosis prevalence, incidence; (2) tuberculosis prevalence, incidence</td>
<td>(1) 927 cases of tuberculosis/100 000 in ECF arm vs 711 in non-ECF arm (aRR, 1.11 [95% CI, 0.87–1.42]); 1.41% infection incidence in ECF arm vs 1.06% in non-ECF arm (aRR, 1.36 [95% CI, 0.59–3.14]); (2) 746 cases of tuberculosis/100 000 in household care arm vs 833 in non-household care arm (aRR, 0.78 [95% CI, 0.61–1.00]); 0.87% infection incidence in household care arm vs 1.71% in non-household care arm (RR, 1.36 [95% CI, 0.59–3.14])</td>
</tr>
<tr>
<td>Brazil, 2010 [49]</td>
<td>Urban communities (n = 8)</td>
<td>CRT (favelas)</td>
<td>Tuberculosis screening plus IPT in household contacts</td>
<td>Tuberculosis incidence</td>
<td>358 cases/100 000 in control arm vs 305 in intervention arm (P = 0.04)</td>
</tr>
<tr>
<td>South Africa, 2011 [29]</td>
<td>Gold mines (n = 16 clusters)</td>
<td>CRT (mines)</td>
<td>Community-wide tuberculosis screening and IPT</td>
<td>Tuberculosis incidence</td>
<td>3.02 cases/100 person-years in intervention arm vs 2.95 in control arm (aRR, 0.96 [95% CI, 0.76–1.21])</td>
</tr>
<tr>
<td>Brazil, 2013 [50]</td>
<td>Rio de Janeiro, HIV clinics (n = 29)</td>
<td>CRT (HIV clinics), step wedge</td>
<td>IPT promotion</td>
<td>Incidence of tuberculosis alone, incidence of tuberculosis and death</td>
<td>1.1 cases of tuberculosis/100 person-years in intervention arm vs 1.31 in control arm (aRR, 0.73 [95% CI, 0.54–0.99]); 3.04 cases of tuberculosis and deaths/100 person-years vs 3.64 in control arm (aRR, 0.89 [95% CI, 0.57–1.39])</td>
</tr>
</tbody>
</table>

Data are adapted and expanded from the article by Kranzer et al [51], which used a nonsystematic literature review and was therefore not comprehensive.

Abbreviations: aHR, adjusted hazard ratio; aRR, adjusted rate ratio; CI, confidence interval; CRT, cluster randomized trial; ECF, enhanced case finding; HIV, human immunodeficiency virus; IPT, isoniazid preventive therapy; M. tuberculosis, Mycobacterium tuberculosis; RR, rate ratio.
The Centers for Disease Control and Prevention (CDC) and the South African Medical Research Council co-hosted the event.

Supplement sponsorship. This work is part of a supplement sponsored by the Centers for Disease Control and Prevention and the National Institutes of Health.

Potential conflicts of interest. All authors: No reported conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References

36. Shanaube K. The association between the magnitude of T-cell interferon-gamma responses to Mycobacterium tuberculosis specific antigens and risk of progression to tuberculosis in household contacts tested with Quantiferon-TB Gold In-Tube assay [dissertation]. London, UK: London School of Hygiene and Tropical Medicine, 2014.


